電腦藥物發現的全球市場：市場規模和佔有率分析 - 趨勢、驅動因素、競爭格局、未來預測（2024-2030）

市場概況

2023 年，全球電腦模擬藥物發現市場收入為 28.297 億美元，預計到 2030 年將達到 56.914 億美元，預測期內複合年增長率為 10.6%。 該行業的成長是由對減少用藥錯誤的日益關注、計算生物學的技術進步以及基於雲端的藥物發現的日益使用所推動的。

此外，計算生物學的進步以及定序的分析階段正在促進數據處理的簡化，從而縮短週轉時間並獲得更準確的結果。 所有這些增強功能正在推動靈活節點優化和儲存整合的新趨勢，主要行業領導者都在關注這一趨勢。

雲端控制軟體的日益普及是推動電腦模擬藥物發現市場成長的主要因素之一。 雲端運算提供了幾乎無限的運算資源的機會，使藥物研究人員能夠獲得適合其需求的運算能力。

關鍵見解

2023 年，人工智慧 (AI) 類別以超過 65% 的佔有率引領市場。 這是由醫療保健數據數位化程度不斷提高所推動的。

SaaS 類別預計將以約 10.8% 的複合年增長率成長。

預計 CRO（合約研究組織）在預測期內的複合年增長率將超過 11.0%，從而降低公司的藥物開發成本。

依地區劃分，到 2023 年，北美將佔全球電腦模擬藥物發現產業佔有率的 50%。 這是由罕見疾病治療的需求以及生物製藥公司增加的研發投資所推動的。

在美國，醫療和研發投資大幅擴張，2020年達到約2,500億美元，為產業成長做出了貢獻。

在旨在改善患者健康的努力的推動下，亞太地區的電腦藥物發現產業取得了顯著的發展，主要是在基於軟體的技術方面。

本報告分析了全球電腦模擬藥物發現市場，包括市場的基本結構和最新情況、主要促進和限制因素以及全球、依地區和主要國家（以貨幣形式計算）的市場規模前景，2017-2030 ），依產品、工作流程、應用程式和最終用戶劃分的詳細趨勢、市場競爭的現狀以及主要公司的概況。

目錄

第一章研究範圍

第二章研究方法

第 3 章執行摘要

第 4 章市場指標

第五章產業展望

• 市場動態
  • 趨勢
  • 促進因素
  • 抑制因素/課題
  • 促進/抑制因子影響分析
• 新型冠狀病毒感染 (COVID-19) 的影響
• 波特五力分析

第六章世界市場

• 摘要
• 市場收入：依產品分類（2017-2030 年）
• 市場收入：依工作流程分類（2017-2030 年）
• 市場收入：依技術劃分（2017-2030 年）
• 市場收入：以最終用戶劃分（2017-2030 年）
• 市場收入：依地區劃分（2017-2030 年）

第七章北美市場

• 摘要
• 市場收入：依產品分類（2017-2030 年）
• 市場收入：依工作流程分類（2017-2030 年）
• 市場收入：依技術劃分（2017-2030 年）
• 市場收入：以最終用戶劃分（2017-2030 年）
• 市場收入：依國家/地區劃分（2017-2030 年）

第8章歐洲市場

第9章亞太市場

第10章拉丁美洲市場

第十一章中東及非洲市場

第12章美國市場

• 摘要
• 市場收入：依產品分類（2017-2030 年）
• 市場收入：依工作流程分類（2017-2030 年）
• 市場收入：依技術劃分（2017-2030 年）
• 市場收入：以最終用戶劃分（2017-2030 年）

第十三章加拿大市場

第14章德國市場

第十五章法國市場

第十六章英國市場

第十七章義大利市場

第十八章西班牙市場

第十九章日本市場

第20章中國市場

第21章印度市場

第22章澳洲市場

第23章韓國市場

第24章巴西市場

第25章墨西哥市場

第26章沙烏地阿拉伯市場

第27章南非市場

第 28 章阿聯酋 (UAE) 市場

第29章競爭態勢

• 市場參與者及其提供的產品/服務的列表
• 主要公司的競爭基準
• 各大公司的產品基準
• 近期策略發展狀況

第30章公司簡介

• chrodinger Inc.
• Dassault Systemes
• OpenEye Scientific Software
• Chemical Computing Group
• Cresset Biomolecular Discovery Limited
• Insilico Medicine
• Atomwise Inc.
• Evotec
• Charles River Laboratories
• Ligand Pharmaceuticals Incorporated
• Simulation Plus

第31章附錄

Market Overview

The worldwide in-silico drug discovery produced a revenue of USD 2,829.7 million in 2023 and is projected to touch USD 5,691.4 million by 2030, growing at a CAGR of 10.6% over the projection period. The development of the industry can be credited to the growing emphasis on decreasing medication mistakes, technical improvements in computational biology, and the rising use of cloud-based applications in drug discovery.

The worldwide in-silico drug discovery market is also propelled by the fast technical advances in the field of computational biology. Computational methods have been effective in the growth of new medicinal molecules.

In addition, advances in computational biology facilitate the simplification of data processing along with analysis phases of sequencing producing shorter turnaround times and accurate results. All the enhancements have triggered a new trend of flexible node optimization and storage integration that major industry leaders are looking into.

Such integration is expected to decrease the amount of transfer data and to solve the queues in data processing, which in principle will eliminate the downlink from the computational analytical community to the ground.

The growing prevalence of cloud control software is one of the main forces driving the in-silico drug discovery market growth. Researchers who study pharmaceuticals can secure access to the amount of computational power that meets their needs because cloud computing provides the opportunity to get almost unlimited computational resources.

Key Insights

In 2023, the AI category led the market with more than 65% share, propelled by augmented data digitization in health care.

Artificial intelligence confronts issues like analyzing multifaceted clinical difficulties and quickening therapeutic target validation in medication discovery.

It helps in the designing of drugs, chemical synthesis, monitoring, polypharmacology, and repurposing, making it essential to numerous stages of drug advancement.

The SaaS category is estimated to advance at a CAGR of around 10.8% in the in-silico drug discovery industry.

Acceptance of SaaS aids in reducing prices and time taken in drug discovery procedures.

SaaS channels are extensively utilized for virtual screening and aim fishing in drug discovery.

Contract Research Organizations are projected to advance at a CAGR of more than 11.0% during the projection period, decreasing costs for businesses in drug development.

Working with a contract research organization provides sponsors not only with an advantage over the traditional clinical studies but also with a quick opportunity to obtain an entire package of trial solutions for the studies to be successful.

The computer application with the largest market resource was introduced in 2021, commonly used for new drug medication designing and in ADME-tox modeling and off-target prediction.

Pharmacophore systematics is usually used concurrently with molecular docking simulations in order to improve the efficiency of virtual screening assays.

In 2023, the North American region help 50% of the worldwide in-silico drug discovery industry share, boosted by the need for treatments for rare illnesses and augmented research and development investments by biopharmaceutical businesses.

The U.S. experienced substantial development in medical and research and development investments, attaining around USD 250 billion in 2020, contributing to industry growth.

The APAC in-silico drug discovery industry has witnessed prominent development, mainly in software-based techs, reinforced by initiatives aimed at advancing patient health.

Table of Contents

Chapter 1. Research Scope

• 1.1. Research Objectives
• 1.2. Market Definition
• 1.3. Analysis Period
• 1.4. Market Size Breakdown by Segments
  • 1.4.1. Market size breakdown, by product
  • 1.4.2. Market size breakdown, by workflow
  • 1.4.3. Market size breakdown, by technology
  • 1.4.4. Market size breakdown, by end user
  • 1.4.5. Market size breakdown, by region
  • 1.4.6. Market size breakdown, by country
• 1.5. Market Data Reporting Unit
  • 1.5.1. Value
• 1.6. Key Stakeholders

Chapter 2. Research Methodology

• 2.1. Secondary Research
  • 2.1.1. Paid
  • 2.1.2. Unpaid
  • 2.1.3. P&S Intelligence database
• 2.2. Primary Research
• 2.3. Market Size Estimation
• 2.4. Data Triangulation
• 2.5. Currency Conversion Rates
• 2.6. Assumptions for the Study
• 2.7. Notes and Caveats

Chapter 3. Executive Summary

Chapter 4. Market Indicators

Chapter 5. Industry Outlook

• 5.1. Market Dynamics
  • 5.1.1. Trends
  • 5.1.2. Drivers
  • 5.1.3. Restraints/challenges
  • 5.1.4. Impact analysis of drivers/restraints
• 5.2. Impact of COVID-19
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Bargaining power of buyers
  • 5.3.2. Bargaining power of suppliers
  • 5.3.3. Threat of new entrants
  • 5.3.4. Intensity of rivalry
  • 5.3.5. Threat of substitutes

Chapter 6. Global Market

• 6.1. Overview
• 6.2. Market Revenue, by Product (2017-2030)
• 6.3. Market Revenue, by Workflow (2017-2030)
• 6.4. Market Revenue, by Technology (2017-2030)
• 6.5. Market Revenue, by End User (2017-2030)
• 6.6. Market Revenue, by Region (2017-2030)

Chapter 7. North America Market

• 7.1. Overview
• 7.2. Market Revenue, by Product (2017-2030)
• 7.3. Market Revenue, by Workflow (2017-2030)
• 7.4. Market Revenue, by Technology (2017-2030)
• 7.5. Market Revenue, by End User (2017-2030)
• 7.6. Market Revenue, by Country (2017-2030)

Chapter 8. Europe Market

• 8.1. Overview
• 8.2. Market Revenue, by Product (2017-2030)
• 8.3. Market Revenue, by Workflow (2017-2030)
• 8.4. Market Revenue, by Technology (2017-2030)
• 8.5. Market Revenue, by End User (2017-2030)
• 8.6. Market Revenue, by Country (2017-2030)

Chapter 9. APAC Market

• 9.1. Overview
• 9.2. Market Revenue, by Product (2017-2030)
• 9.3. Market Revenue, by Workflow (2017-2030)
• 9.4. Market Revenue, by Technology (2017-2030)
• 9.5. Market Revenue, by End User (2017-2030)
• 9.6. Market Revenue, by Country (2017-2030)

Chapter 10. LATAM Market

• 10.1. Overview
• 10.2. Market Revenue, by Product (2017-2030)
• 10.3. Market Revenue, by Workflow (2017-2030)
• 10.4. Market Revenue, by Technology (2017-2030)
• 10.5. Market Revenue, by End User (2017-2030)
• 10.6. Market Revenue, by Country (2017-2030)

Chapter 11. MEA Market

• 11.1. Overview
• 11.2. Market Revenue, by Product (2017-2030)
• 11.3. Market Revenue, by Workflow (2017-2030)
• 11.4. Market Revenue, by Technology (2017-2030)
• 11.5. Market Revenue, by End User (2017-2030)
• 11.6. Market Revenue, by Country (2017-2030)

Chapter 12. U.S. Market

• 12.1. Overview
• 12.2. Market Revenue, by Product (2017-2030)
• 12.3. Market Revenue, by Workflow (2017-2030)
• 12.4. Market Revenue, by Technology (2017-2030)
• 12.5. Market Revenue, by End User (2017-2030)

Chapter 13. Canada Market

• 13.1. Overview
• 13.2. Market Revenue, by Product (2017-2030)
• 13.3. Market Revenue, by Workflow (2017-2030)
• 13.4. Market Revenue, by Technology (2017-2030)
• 13.5. Market Revenue, by End User (2017-2030)

Chapter 14. Germany Market

• 14.1. Overview
• 14.2. Market Revenue, by Product (2017-2030)
• 14.3. Market Revenue, by Workflow (2017-2030)
• 14.4. Market Revenue, by Technology (2017-2030)
• 14.5. Market Revenue, by End User (2017-2030)

Chapter 15. France Market

• 15.1. Overview
• 15.2. Market Revenue, by Product (2017-2030)
• 15.3. Market Revenue, by Workflow (2017-2030)
• 15.4. Market Revenue, by Technology (2017-2030)
• 15.5. Market Revenue, by End User (2017-2030)

Chapter 16. U.K. Market

• 16.1. Overview
• 16.2. Market Revenue, by Product (2017-2030)
• 16.3. Market Revenue, by Workflow (2017-2030)
• 16.4. Market Revenue, by Technology (2017-2030)
• 16.5. Market Revenue, by End User (2017-2030)

Chapter 17. Italy Market

• 17.1. Overview
• 17.2. Market Revenue, by Product (2017-2030)
• 17.3. Market Revenue, by Workflow (2017-2030)
• 17.4. Market Revenue, by Technology (2017-2030)
• 17.5. Market Revenue, by End User (2017-2030)

Chapter 18. Spain Market

• 18.1. Overview
• 18.2. Market Revenue, by Product (2017-2030)
• 18.3. Market Revenue, by Workflow (2017-2030)
• 18.4. Market Revenue, by Technology (2017-2030)
• 18.5. Market Revenue, by End User (2017-2030)

Chapter 19. Japan Market

• 19.1. Overview
• 19.2. Market Revenue, by Product (2017-2030)
• 19.3. Market Revenue, by Workflow (2017-2030)
• 19.4. Market Revenue, by Technology (2017-2030)
• 19.5. Market Revenue, by End User (2017-2030)

Chapter 20. China Market

• 20.1. Overview
• 20.2. Market Revenue, by Product (2017-2030)
• 20.3. Market Revenue, by Workflow (2017-2030)
• 20.4. Market Revenue, by Technology (2017-2030)
• 20.5. Market Revenue, by End User (2017-2030)

Chapter 21. India Market

• 21.1. Overview
• 21.2. Market Revenue, by Product (2017-2030)
• 21.3. Market Revenue, by Workflow (2017-2030)
• 21.4. Market Revenue, by Technology (2017-2030)
• 21.5. Market Revenue, by End User (2017-2030)

Chapter 22. Australia Market

• 22.1. Overview
• 22.2. Market Revenue, by Product (2017-2030)
• 22.3. Market Revenue, by Workflow (2017-2030)
• 22.4. Market Revenue, by Technology (2017-2030)
• 22.5. Market Revenue, by End User (2017-2030)

Chapter 23. South Korea Market

• 23.1. Overview
• 23.2. Market Revenue, by Product (2017-2030)
• 23.3. Market Revenue, by Workflow (2017-2030)
• 23.4. Market Revenue, by Technology (2017-2030)
• 23.5. Market Revenue, by End User (2017-2030)

Chapter 24. Brazil Market

• 24.1. Overview
• 24.2. Market Revenue, by Product (2017-2030)
• 24.3. Market Revenue, by Workflow (2017-2030)
• 24.4. Market Revenue, by Technology (2017-2030)
• 24.5. Market Revenue, by End User (2017-2030)

Chapter 25. Mexico Market

• 25.1. Overview
• 25.2. Market Revenue, by Product (2017-2030)
• 25.3. Market Revenue, by Workflow (2017-2030)
• 25.4. Market Revenue, by Technology (2017-2030)
• 25.5. Market Revenue, by End User (2017-2030)

Chapter 26. Saudi Arabia Market

• 26.1. Overview
• 26.2. Market Revenue, by Product (2017-2030)
• 26.3. Market Revenue, by Workflow (2017-2030)
• 26.4. Market Revenue, by Technology (2017-2030)
• 26.5. Market Revenue, by End User (2017-2030)

Chapter 27. South Africa Market

• 27.1. Overview
• 27.2. Market Revenue, by Product (2017-2030)
• 27.3. Market Revenue, by Workflow (2017-2030)
• 27.4. Market Revenue, by Technology (2017-2030)
• 27.5. Market Revenue, by End User (2017-2030)

Chapter 28. U.A.E. Market

• 28.1. Overview
• 28.2. Market Revenue, by Product (2017-2030)
• 28.3. Market Revenue, by Workflow (2017-2030)
• 28.4. Market Revenue, by Technology (2017-2030)
• 28.5. Market Revenue, by End User (2017-2030)

Chapter 29. Competitive Landscape

• 29.1. List of Market Players and their Offerings
• 29.2. Competitive Benchmarking of Key Players
• 29.3. Product Benchmarking of Key Players
• 29.4. Recent Strategic Developments

Chapter 30. Company Profiles

• 30.1. chrodinger Inc.
  • 30.1.1. Business overview
  • 30.1.2. Product and service offerings
  • 30.1.3. Key financial summary
• 30.2. Dassault Systemes
  • 30.2.1. Business overview
  • 30.2.2. Product and service offerings
  • 30.2.3. Key financial summary
• 30.3. OpenEye Scientific Software
  • 30.3.1. Business overview
  • 30.3.2. Product and service offerings
  • 30.3.3. Key financial summary
• 30.4. Chemical Computing Group
  • 30.4.1. Business overview
  • 30.4.2. Product and service offerings
  • 30.4.3. Key financial summary
• 30.5. Cresset Biomolecular Discovery Limited
  • 30.5.1. Business overview
  • 30.5.2. Product and service offerings
  • 30.5.3. Key financial summary
• 30.6. Insilico Medicine
  • 30.6.1. Business overview
  • 30.6.2. Product and service offerings
  • 30.6.3. Key financial summary
• 30.7. Atomwise Inc.
  • 30.7.1. Business overview
  • 30.7.2. Product and service offerings
  • 30.7.3. Key financial summary
• 30.8. Evotec
  • 30.8.1. Business overview
  • 30.8.2. Product and service offerings
  • 30.8.3. Key financial summary
• 30.9. Charles River Laboratories
  • 30.9.1. Business overview
  • 30.9.2. Product and service offerings
  • 30.9.3. Key financial summary
• 30.10. Ligand Pharmaceuticals Incorporated
  • 30.10.1. Business overview
  • 30.10.2. Product and service offerings
  • 30.10.3. Key financial summary
• 30.11. Simulation Plus
  • 30.11.1. Business overview
  • 30.11.2. Product and service offerings
  • 30.11.3. Key financial summary

Chapter 31. Appendix

• 31.1. Abbreviations
• 31.2. Sources and References
• 31.3. Related Reports